HALLE, Germany--(BUSINESS WIRE)--Novosom AG today announced that it has been granted patents for both the USA and Europe for its Drug Delivery technology Smarticles®. Smarticles® are fully charge reversible liposomes for the in vivo drug delivery of nucleotides like siRNA or antisense to targeted cells. At the same time Novosom announced that it has been selected to present at both BioEquity (May 28-29, 2008, Hotel Okura, Amsterdam, the Netherlands) and the 2008 BIO Business Forum which takes place during BIO2008 (June 17-20, 2008, San Diego Convention Center, California, USA).
